Literature DB >> 17295567

Fluoxetine, smoking, and history of major depression: A randomized controlled trial.

Bonnie Spring1, Neal Doran, Sherry Pagoto, Dennis McChargue, Jessica Werth Cook, Katherine Bailey, John Crayton, Donald Hedeker.   

Abstract

The study was a randomized placebo-controlled trial testing whether fluoxetine selectively enhances cessation for smokers with a history of depression. Euthymic smokers with (H+, n = 109) or without (H-, n = 138) a history of major depression received 60 mg fluoxetine or placebo plus group behavioral quit-smoking treatment for 12 weeks. Fluoxetine initially enhanced cessation for H+ smokers (p = .02) but subsequently impaired cessation regardless of depressive history. Six months after quit date, fluoxetine-treated participants were 3.3 times more likely to be smoking (p = .02). Further research is warranted to determine why high-dose fluoxetine produces continuing effects that oppose tobacco abstinence. Copyright 2007 APA, all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17295567     DOI: 10.1037/0022-006X.75.1.85

Source DB:  PubMed          Journal:  J Consult Clin Psychol        ISSN: 0022-006X


  14 in total

1.  Influence of PTSD symptom clusters on smoking status among help-seeking Iraq and Afghanistan veterans.

Authors:  Jessica Cook; Matthew Jakupcak; Robert Rosenheck; Alan Fontana; Miles McFall
Journal:  Nicotine Tob Res       Date:  2009-07-31       Impact factor: 4.244

Review 2.  Past major depression and smoking cessation outcome: a systematic review and meta-analysis update.

Authors:  Brian Hitsman; George D Papandonatos; Dennis E McChargue; Andrew DeMott; María José Herrera; Bonnie Spring; Belinda Borrelli; Raymond Niaura
Journal:  Addiction       Date:  2013-02       Impact factor: 6.526

3.  A naturalistic study of the association between antidepressant treatment and outcome of smoking cessation treatment.

Authors:  Todd Zorick; Mark A Mandelkern; Arthur L Brody
Journal:  J Clin Psychiatry       Date:  2014-12       Impact factor: 4.384

4.  Smoking cue reactivity in adult smokers with and without depression: a pilot study.

Authors:  Andrea H Weinberger; Sherry A McKee; Tony P George
Journal:  Am J Addict       Date:  2012 Mar-Apr

5.  Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment.

Authors:  David R Strong; Christopher W Kahler; Adam M Leventhal; Ana M Abrantes; Elizabeth Lloyd-Richardson; Raymond Niaura; Richard A Brown
Journal:  Nicotine Tob Res       Date:  2009-07-02       Impact factor: 4.244

6.  Randomized controlled trial of behavioral activation smoking cessation treatment for smokers with elevated depressive symptoms.

Authors:  Laura MacPherson; Matthew T Tull; Alexis K Matusiewicz; Samantha Rodman; David R Strong; Christopher W Kahler; Derek R Hopko; Michael J Zvolensky; Richard A Brown; C W Lejuez
Journal:  J Consult Clin Psychol       Date:  2010-02

7.  Effects of sequential fluoxetine and gender on prequit depressive symptoms, affect, craving, and quit day abstinence in smokers with elevated depressive symptoms: a growth curve modeling approach.

Authors:  Haruka Minami; Christopher W Kahler; Erika Litvin Bloom; Mark A Prince; Ana M Abrantes; David R Strong; Raymond Niaura; Ivan W Miller; Kathleen M Palm Reed; Lawrence H Price; Richard A Brown
Journal:  Exp Clin Psychopharmacol       Date:  2014-08-04       Impact factor: 3.157

8.  Nicotine effects on affective response in depression-prone smokers.

Authors:  Bonnie Spring; Jessica Werth Cook; Bradley Appelhans; Anne Maloney; Malia Richmond; Jocelyn Vaughn; Joseph Vanderveen; Donald Hedeker
Journal:  Psychopharmacology (Berl)       Date:  2007-10-25       Impact factor: 4.530

Review 9.  Antidepressants for smoking cessation.

Authors:  John R Hughes; Lindsay F Stead; Jamie Hartmann-Boyce; Kate Cahill; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2014-01-08

Review 10.  New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?

Authors:  Emma Beard; Lion Shahab; Damian M Cummings; Susan Michie; Robert West
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.